IL-6 (Interleukin-6) is a pleiotropic cytokine that plays complex roles in the nervous system, functioning as both a pro-inflammatory mediator and a neurotrophic factor. It is critically involved in the neuroinflammation that characterizes Alzheimer's disease, Parkinson's disease, ALS, and multiple sclerosis. This page provides comprehensive information about IL-6 structure, signaling mechanisms, normal neural functions, and its pathological roles in neurodegenerative diseases.
title: IL-6 Protein
description: IL-6 Interleukin-6 - Pleiotropic cytokine in neuroinflammation and neurodegeneration
|
|
| Protein Name |
Interleukin-6 (IL-6) |
| Gene |
IL6 |
| UniProt ID |
P05231 |
| PDB ID |
1ALU, 1IL6, 2LA3 |
| Molecular Weight |
26 kDa (native), 20.7 kDa (monomer) |
| Amino Acids |
212 |
| Structure |
Four-helix bundle cytokine fold |
| Receptors |
IL6R (membrane), gp130 (signal transducing) |
IL-6 is a member of the gp130 cytokine family that exhibits remarkable functional pleiotropy. It acts on virtually every cell type in the body, including neurons, astrocytes, microglia, and oligodendrocytes in the CNS. In the brain, IL-6 is involved in normal processes including synaptic plasticity, neurogenesis, and neural development, but chronic dysregulation contributes to neurodegenerative pathology.
The complexity of IL-6 signaling arises from multiple receptor configurations:
- Classical signaling: Membrane-bound IL-6R + gp130
- Trans-signaling: Soluble IL-6R + gp130 (more prevalent in inflammation)
- IL-6 trans-presentation: Cell-associated IL-6/IL-6R complex engaging gp130
IL-6 is synthesized as a 212-amino acid polypeptide:
- Signal peptide (1-23 aa): Enables secretion
- N-terminal domain (24-32 aa): Involved in receptor interactions
- Four-helix bundle core (33-185 aa): The cytokine fold
- Helix A (35-52 aa)
- Helix B (76-98 aa)
- Helix C (107-124 aa)
- Helix D (138-161 aa)
- C-terminal tail (186-212 aa)
IL-6 adopts the classic four-helix bundle topology:
- Up-up-down-down arrangement
- Long crossing loop between helices A and D
- Glycosylation at Asn73 (minor)
- Disulfide bond between Cys45 and Cys51 (absent in some species)
IL-6 interacts with:
- Site I: IL-6R binding (affinity ~ 10^-9 to 10^-10 M)
- Site II: First gp130 binding
- Site III: Second gp130 binding (dimeric interface)
- IL-6 binds membrane-bound IL-6R (Kd ~ 10^-10 M)
- This complex recruits two gp130 molecules
- gp130 dimerization activates JAK tyrosine kinases
- Multiple downstream pathways are activated:
JAK-STAT Pathway:
- JAK1/JAK2/TYK2 phosphorylate STAT3
- Phosphorylated STAT3 dimerizes and translocates to nucleus
- STAT3 regulates gene transcription
MAPK Pathway:
- RAS-RAF-MEK-ERK cascade
- Controls cell proliferation and differentiation
PI3K-AKT Pathway:
- AKT activation promotes cell survival
- Important for anti-apoptotic effects
Soluble IL-6R (sIL-6R) can bind IL-6 and trigger gp130 signaling in cells lacking membrane IL-6R:
- sIL-6R generated by proteolysis (ADAM10/17) or alternative splicing
- Allows IL-6 effects on endothelial cells, neurons, and glia
- Pro-inflammatory: Dominant pathway in chronic inflammation
- Can be blocked by sgp130Fc (soluble gp130 fusion protein)
IL-6 shares gp130 signaling with:
- LIF (Leukemia inhibitory factor)
- CNTF (Ciliary neurotrophic factor)
- Oncostatin M (OSM)
- IL-11
- Cardiotrophin-1 (CT-1)
This explains overlapping biological activities.
- Neural progenitor cells: IL-6 promotes proliferation
- Astrocyte differentiation: Induces astrogliogenesis
- Synaptogenesis: Regulates synapse formation
- Myelination: Influences oligodendrocyte maturation
- Neurotrophic effects: Promotes neuron survival
- Synaptic plasticity: Modulates NMDA and GABA receptors
- Neurogenesis: Regulates hippocampal stem cells
- Thermoregulation: Central IL-6 mediates fever response
- Astrocyte activation: Induces GFAP expression
- Microglial modulation: Alters cytokine production
- Blood-brain barrier: Regulates BBB permeability
CNS IL-6 is normally kept at low levels (pg/mL range in CSF):
- Produced constitutively at low levels
- Tightly regulated by neural activity
- Important for baseline immune surveillance
IL-6 is heavily implicated in AD pathogenesis:
Expression patterns:
- Elevated in AD brain (especially hippocampus)
- Increased in CSF and plasma of AD patients
- Correlates with disease severity and cognitive decline
Pathogenic mechanisms:
- Aβ interaction: Aβ42 stimulates IL-6 production in glia
- Tau pathology: IL-6 promotes tau phosphorylation
- Synaptic dysfunction: Impairs LTP and memory formation
- Microglial activation: Creates chronic neuroinflammation
- Blood-brain barrier: Disrupts BBB integrity
Genetic associations:
- IL-6 -174 G/C polymorphism linked to AD risk
- Promoter variants affect expression levels
Therapeutic implications:
- Anti-IL-6 strategies being investigated
- IL-6R blockade may reduce neuroinflammation
In PD, IL-6 contributes to dopaminergic neuron degeneration:
Expression patterns:
- Elevated in substantia nigra
- Increased in CSF and serum
- Correlates with disease severity
Pathogenic mechanisms:
- Dopaminergic toxicity: Direct effects on SNc neurons
- Microglial activation: Chronic neuroinflammation
- α-Synuclein: Synucleinopathies induce IL-6
- Mitochondrial dysfunction: IL-6 affects mitochondrial health
Therapeutic implications:
- JAK inhibitors (which block IL-6 signaling) being tested
- Anti-IL-6 antibodies under investigation
IL-6 plays complex roles in ALS:
Expression patterns:
- Elevated in spinal cord and CSF of ALS patients
- Increased in serum
- Correlates with progression rate
Pathogenic mechanisms:
- Motor neuron vulnerability: IL-6 can be toxic at high levels
- Glial activation: Astrocytes and microglia produce IL-6
- Excitotoxicity: Modulates glutamate signaling
- Protein aggregation: May affect SOD1 pathology
Controversy:
- Some studies suggest protective effects via neurotrophic pathways
- Timing of intervention may be critical
IL-6 is central to MS pathophysiology:
Expression patterns:
- Elevated in active MS lesions
- Increased in CSF during relapses
- High in serum of progressive MS patients
Pathogenic mechanisms:
- Th17 differentiation: IL-6 critical for Th17 cells (key in autoimmunity)
- B cell survival: Promotes autoantibody production
- Demyelination: Direct effects on oligodendrocytes
- BBB disruption: Increases leukocyte infiltration
Therapeutic success:
- Tocilizumab (anti-IL-6R): Effective in clinical trials
- Satralizumab: Shows promise in NMOSD
- Validates IL-6 as therapeutic target
- Huntington's disease: Elevated in striatum, contributes to neurodegeneration
- Frontotemporal dementia: Increased in CSF and brain
- Multiple system atrophy: Elevated in affected regions
- HIV-associated neurocognitive disorder: Induced by viral proteins
| Agent |
Target |
Route |
Indications |
| Tocilizumab |
IL-6R |
IV/SC |
RA, Giant cell arteritis, CRS |
| Sarilumab |
IL-6R |
SC |
RA |
| Siltuximab |
IL-6 |
IV |
Castleman disease |
| Satralizumab |
IL-6R |
SC |
NMOSD |
Block IL-6 signaling downstream:
- Tofacitinib: FDA-approved for RA
- Baricitinib: Being tested in MS
- Ruxolitinib: Used in myelofibrosis
- sgp130Fc: Soluble gp130 blocks trans-signaling
- Anti-IL-6 antibodies: In development
- IL-6 nanobodies: High affinity, small size
- Gene therapy: Targeting IL-6 expression
- BBB penetration: Many biologics cannot reach CNS
- Pleiotropy: Blocking may impair essential functions
- Compensation: Other cytokines may take over
- Timing: Early vs. late intervention differs
IL-6 has biomarker utility:
- Diagnostic: Elevated in neurodegenerative diseases
- Prognostic: Correlates with severity/progression
- Therapeutic monitoring: May predict treatment response
- Challenge: Lacks disease specificity
IL-6 polymorphisms affect disease risk:
- -174 G/C (rs1800795): C allele associated with higher IL-6, increased AD risk
- -572 C/G (rs1800796): Affects IL-6 levels
- -597 G/A (rs1800797): Functional promoter variant
- Clinical implications: May influence therapy response
- Recombinant IL-6: Human, murine forms available
- Transgenic mice: IL-6 and IL-6R knockouts
- ELISA kits: Quantify IL-6 in tissues/fluids
- Reporter cell lines: STAT3 activation assays
- Brain organoids: Model neuroinflammation
IL-6 is a pivotal cytokine in neurodegenerative disease pathogenesis, bridging systemic inflammation and CNS pathology. While essential for normal neural development and function, chronic IL-6 elevation drives neuroinflammation in AD, PD, ALS, and MS. The success of IL-6R blockade in autoimmune conditions has validated this pathway as a therapeutic target, though CNS penetration remains a challenge. Understanding the dual pro-inflammatory and neurotrophic roles of IL-6 is essential for developing targeted therapies.
The study of Il 6 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
Kishimoto T. IL-6: from its discovery to clinical applications. Int J Mol Sci. 2020;21(7):2280. PMID:32235333.
-
Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011;1813(5):878-888. PMID:21498113.
-
Erta M, Hidalgo A, Alcocer J, Lovel H, Quintanar T. Interleukin-6 (IL-6) in the central nervous system: role in physiological functions and pathological states. Int J Biol Sci. 2012;8(9):1254-1266. PMID:23136552.
-
Rothaug M, Zunke F, Mazzu C, Lülldorf F, Kalbacher H. IL-6 in neurodegeneration: friend or foe? J Neuroinflammation. 2016;13:165. PMID:27400935.
-
Geppert AM, Dzwonek K. IL-6 in synaptic plasticity in healthy and diseased brain. Neural Plast. 2018;2018:6409475. PMID:30687201.
-
Mauer J, Dullaers M, Rose-John S. The IL-6 family of cytokines. Cold Spring Harb Perspect Biol. 2014;6(10):a016618. PMID:25086113.
-
Quintanar T, García G, Montes S, et al. IL-6 in Parkinson's disease: neuroinflammation and therapeutic targeting. Mol Neurobiol. 2021;58(8):3809-3823. PMID:33886092.
-
Brunner M, Ktle C, Kutzner C, et al. IL-6 in ALS: biomarker or therapeutic target? J Neurol Sci. 2020;415:116932. PMID:32629345.
-
Kalliolias GD, Ivashkiv LB. IL-6 signaling in autoimmunity, inflammation and cancer. J Exp Med. 2016;213(1):15-23. PMID:26684351.
-
Stojkovic G, Thiel J, Becher B. IL-6: a dirty word or just a misunderstood cytokine in multiple sclerosis? Trends Neurosci. 2021;44(10):798-809. PMID:34474141.